Comparative Analysis Reports Superiority of OncoSil™ Over Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer

News

Comparative Analysis Reports Superiority of OncoSil™ Over Stereotactic Body Radiation Therapy in Patients with Pancreatic Cancer

Sydney, Australia – 7 May 2025: OncoSil Medical Ltd (ASX: OSL) (OncoSil or the Company), a medical device company focused on localised treatments for patients with locally advanced pancreatic cancer (LAPC), is pleased to announce the results of the first comparative analysis of outcomes in patients with unresectable or borderline-resectable locally advanced pancreatic cancer (LAPC) receiving either OncoSil™ or Stereotactic Body Radiation Therapy (SBRT) in addition to chemotherapy. The analysis is the first comparison of these two different forms of radiotherapy and the results demonstrate the superiority of OncoSil™ in extending overall survival, progression-free survival (PFS) and the rate of downstaging and surgical resection, among other outcomes.

The retrospective, investigator-initiated analysis examined outcomes in more than 100 patients with LAPC treated over an eight-year period at the Royal Adelaide Hospital, South Australia: 42 patients received  OncoSil™ plus chemotherapy vs. 59 patients received induction chemotherapy followed by SBRT between  March 2015 and August 2023. The two cohorts of patients were statistically similar in terms of their age, sex, performance status, burden of pancreatic cancer and chemotherapy regimen used.

The results demonstrate a significantly prolonged overall survival in patients treated with OncoSil™  (median survival: 22 months for OncoSil™ vs. 14 months for SBRT; Hazard Ratio [HR] for SBRT: 1.98;  p=0.004), as well as significantly longer local and distant PFS (HR: 1.61; p=0.034, and HR: 1.71; p=0.019,  respectively). The rate of downstaging was significantly greater in patients treated with OncoSil™ compared to SBRT (24% vs. 4.7%; p<0.001), as was the proportion of patients undergoing surgical resection (22% vs. 0%; p<0.001).

The frequency of adverse events (AEs) reported was similar in both cohorts, although numerically lower in patients treated with OncoSil™ (grade 3 AEs 0% with OncoSil™ vs. 7.3% with SBRT; p=0.098; no grade 4 or 5 AEs in either cohort).

The analysis was performed by investigators at the Royal Adelaide Hospital, South Australia, and presented at the Digestive Disease Week (DDW2025) scientific meeting in San Diego, USA, 3–6 May 2025, by Dr Amanda Lim, an advanced endoscopy fellow at Beth Israel Deaconess Medical Centre in Boston, MA, USA, and an academic researcher from RAH.

The analysis marks another significant milestone for OncoSil Medical, as the presentation provided the first comparative study of OncoSil™ vs. SBRT, which is widely regarded as the most targeted form of external beam radiation therapy, in patients with LAPC receiving standard-of-care chemotherapy.